Short answer
Dexcom (DXCM) filed an 8-K current report with the SEC on July 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). DexCom reported financial results for the quarter ended June 30, 2026.
Dexcom 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- DexCom reported financial results for the quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1 contains detailed results and additional information
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $1.308B, up 13% YoY; international growth 19% outpaced U.S. growth of 11%
- GAAP operating margin 24.3% versus 18.4% in Q2 2025, signaling substantial operating leverage
- GAAP diluted EPS $0.64 versus $0.45; net income increased to $249.1M from $179.8M
- FY2026 guidance raised to $5.18–$5.25B revenue and approximately 23.5–24% non-GAAP operating margin
- $1.95B cash, cash equivalents and marketable securities with undrawn revolver supports capacity expansion and market opportunities
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Dexcom 8-K filings
Get the next DXCM 8-K as it lands
Follow DXCM for push alerts, or ask the research agent what this filing means.